---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-021712"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:44:25.239603+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Telomir-1 outperforms FDA-approved DFO in reducing intracellular iron in preclinical study

## Summary
- Telomir-1 reduced intracellular Fe²⁺ in human keratinocytes in dose- and time-dependent manner at low-micromolar concentrations.
- Deferoxamine (DFO) exhibited limited intracellular activity under equivalent conditions.
- Telomir-1 formulated with zinc (Telomir-Zn) enables controlled exchange of metal ions – binding excess iron/copper while contributing zinc.
- Findings support research into metal-ion balance, oxidative stress, and epigenetic enzyme dynamics in aging and disease.

## SEC filing metadata
- accession: 0001493152-25-021712
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315225021712/0001493152-25-021712-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315225021712/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-021712
- JSON: https://secwatch.observer/filing/0001493152-25-021712.json
- Plain text: https://secwatch.observer/filing/0001493152-25-021712.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.